This article is more than 5 years old. Information may no longer be current.

TearScience cuts price in half for LipiFlow

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

TearScience announced a 50% reduction in price of the single-use activators for the LipiFlow treatment platform for meibomian gland dysfunction.

The company is striving to make LipiFlow and LipiView technologies more accessible to eye care professionals, according to a press release.

The goal is to encourage professionals to evaluate and intervene earlier in meibomian gland dysfunction (MGD), the company said.

TearScience reported that the change relates to the economies of scale necessary to reorganize and expand its supply and manufacturing capabilities

“By enacting these changes, we are answering the market’s demand for greater accessibility to our core technologies so that eye care professionals can accurately evaluate MGD early in its course and intervene in this progressive disease,” TearScience CEO Joseph Boorady, OD, said in the release.